Results 241 to 250 of about 667,241 (301)

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Rapid Onset of Pulmonary Arterial Hypertension After Liver Transplant-A Case Report. [PDF]

Reports (MDPI)
Redaelli S, Nazemian R, Hackl F, Uthayashankar A, Kaufman M.   +4 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Deep learning-based identification of chronic pulmonary embolism on CTPA: a regional lung analysis using multiplanar MIP images. [PDF]

Eur Radiol Exp
Vainio T, Mäkelä T, Ruohola A, Arkko A, Savolainen S, Kangasniemi M.   +5 more
europepmc   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source

Impact of pulmonary hypertension on mortality in progressive massive fibrosis. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Özgün S, Sarı G, Koyuncu A, Ezber R, Arslan MA, Doğan FM, Koç Ş, Şimşek C.   +7 more
europepmc   +1 more source

Corrigendum to “Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology” [Int J Cardiol Congenit Heart Dis, Volume 7, March 2022, 100331]

International Journal of Cardiology Congenital Heart Disease
Chinthaka B. Samaranayake, Ruth McNiven, Aleksander Kempny, Carl Harries, Laura C. Price, Michael Gatzoulis, Konstantinos Dimopoulos, Stephen J. Wort, Colm McCabe   +8 more
doaj   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Activin A-Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH. [PDF]

Arterioscler Thromb Vasc Biol
Faizah NN, Ryanto GRT, Kencana SMS, Suzuki Y, Hara T, Otake H, Emoto N.   +6 more
europepmc   +1 more source